{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,26]],"date-time":"2026-03-26T16:26:37Z","timestamp":1774542397309,"version":"3.50.1"},"reference-count":123,"publisher":"Bentham Science Publishers Ltd.","issue":"2","content-domain":{"domain":["eurekaselect.com"],"crossmark-restriction":true},"short-container-title":["CNSAMC"],"published-print":{"date-parts":[[2020,9,29]]},"abstract":"<jats:sec>\n<jats:title>:<\/jats:title>\n<jats:p>A vast advancement has been made in the treatment related to central nervous system\ndisorders especially Parkinson\u2019s disease. The development in therapeutics and a better understanding\nof the targets results in upsurge of many promising therapies for Parkinson\u2019s disease. Parkinson\u2019s\ndisease is defined by neuronal degeneration and neuroinflammation and it is reported that\nthe presence of the neurofibrillary aggregates such as Lewy bodies is considered as the marker.\nAlong with this, it is also characterized by the presence of motor and non-motor symptoms, as\nseen in Parkinsonian patients. A lot of treatment options mainly focus on prophylactic measures or\nthe symptomatic treatment of Parkinson\u2019s disease.<\/jats:p>\n<\/jats:sec>\n<jats:sec>\n<jats:title>:<\/jats:title>\n<jats:p>Neuroinflammation and neurodegeneration are the point of interest which can be exploited as a\nnew target to emphasis on Parkinson\u2019s disease.<\/jats:p>\n<\/jats:sec>\n<jats:sec>\n<jats:title>:<\/jats:title>\n<jats:p>A thorough study of these targets helps in modifications of those molecules which are particularly\ninvolved in causing the neuronal degeneration and neuroinflammation in Parkinson\u2019s disease.<\/jats:p>\n<\/jats:sec>\n<jats:sec>\n<jats:title>:<\/jats:title>\n<jats:p>A lot of drug regimens are available for the treatment of Parkinson\u2019s disease, although levodopa\nremains the choice of drug for controlling the symptoms, yet is accompanied with significant\nsnags. It is always suggested to use other drug therapies concomitantly with levodopa.<\/jats:p>\n<\/jats:sec>\n<jats:sec>\n<jats:title>:<\/jats:title>\n<jats:p>A number of significant causes and therapeutic targets for Parkinson\u2019s disease have been identified\nin the last decade, here an attempt was made to highlight the most significant of them. It was\nalso found that the treatment regimen and involvement of therapies are totally dependent on individuals\nand can be tailored to the needs of each individual patient.<\/jats:p>\n<\/jats:sec>","DOI":"10.2174\/1871524920666200705222842","type":"journal-article","created":{"date-parts":[[2020,7,6]],"date-time":"2020-07-06T17:53:41Z","timestamp":1594058021000},"page":"88-102","update-policy":"https:\/\/doi.org\/10.2174\/bsp_crossmark_policy","source":"Crossref","is-referenced-by-count":15,"title":["Understanding the Pathogenesis Involved in Parkinson\u2019s Disease and Potential Therapeutic Treatment Strategies"],"prefix":"10.2174","volume":"20","author":[{"given":"Meenakshi","family":"Dhanawat","sequence":"first","affiliation":[{"name":"M.M. College of Pharmacy, Maharishi Markandeshwar (Deemed to be University), Mullana, Ambala, HR-133207, India"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dinesh K.","family":"Mehta","sequence":"additional","affiliation":[{"name":"M.M. College of Pharmacy, Maharishi Markandeshwar (Deemed to be University), Mullana, Ambala, HR-133207, India"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sumeet","family":"Gupta","sequence":"additional","affiliation":[{"name":"M.M. College of Pharmacy, Maharishi Markandeshwar (Deemed to be University), Mullana, Ambala, HR-133207, India"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rina","family":"Das","sequence":"additional","affiliation":[{"name":"M.M. College of Pharmacy, Maharishi Markandeshwar (Deemed to be University), Mullana, Ambala, HR-133207, India"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"965","reference":[{"key":"ref=1","doi-asserted-by":"publisher","first-page":"115","DOI":"10.4103\/2347-8659.143662","volume":"1","author":"Chao D.W.","year":"2014","unstructured":"Chao D.W.; Piu C.; Clinicogenetics of Parkinson\u2019s disease: Drawing but not completed picture. Neuroimmunol Neuroinflamm 2014,1,115-126","journal-title":"Neuroimmunol Neuroinflamm"},{"key":"ref=2","doi-asserted-by":"publisher","first-page":"819","DOI":"10.1126\/science.1087753","volume":"302","author":"Dawson T.M.","year":"2003","unstructured":"Dawson T.M.; Dawson V.L.; Molecular pathways of neurodegeneration in Parkinson\u2019s disease. Science 2003,302,819-822","journal-title":"Science"},{"key":"ref=3","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1002\/ana.21022","volume":"60","author":"Hardy J.","year":"2006","unstructured":"Hardy J.; Cai H.; Cookson M.R.; Hardy K.G.; Singleton A.; Genetics of Parkinson\u2019s disease and parkinsonism. Ann Neurol 2006,60,389-398","journal-title":"Ann Neurol"},{"key":"ref=4","doi-asserted-by":"publisher","first-page":"641","DOI":"10.1002\/humu.20507","volume":"28","author":"Tan E.K.","year":"2007","unstructured":"Tan E.K.; Skipper L.M.; Pathogenic mutations in Parkinson disease. Hum Mutat 2007,28(7),641-653","journal-title":"Hum Mutat"},{"key":"ref=5","doi-asserted-by":"publisher","first-page":"S343","DOI":"10.1002\/mds.21676","volume":"22","author":"Gasser T.","year":"2007","unstructured":"Gasser T.; Update on the genetics of Parkinson\u2019s disease. Mov Disord 2007,22(Suppl. 17),S343-S350","journal-title":"Mov Disord"},{"key":"ref=6","doi-asserted-by":"publisher","first-page":"244","DOI":"10.1016\/j.tins.2007.03.009","volume":"30","author":"Sulzer D.","year":"2007","unstructured":"Sulzer D.; Multiple hit hypotheses for dopamine neuron loss in Parkinson\u2019s disease. Trends Neurosci 2007,30,244-250","journal-title":"Trends Neurosci"},{"key":"ref=7","doi-asserted-by":"publisher","first-page":"2093","DOI":"10.1212\/01.wnl.0000271880.27321.a7","volume":"69","author":"Klein C.","year":"2007","unstructured":"Klein C.; Schlossmacher M.G.; Parkinson disease, 10 years after its genetic revolution: Multiple clues to a complex disorder. Neurology 2007,69(22),2093-2104","journal-title":"Neurology"},{"key":"ref=8","doi-asserted-by":"publisher","first-page":"R183","DOI":"10.1093\/hmg\/ddm159","volume":"2","author":"Thomas B.","year":"2007","unstructured":"Thomas B.; Beal M.F.; Parkinson\u2019s disease. Hum Mol Genet 2007,2,R183-194","journal-title":"Hum Mol Genet"},{"key":"ref=9","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1111\/j.1745-7254.2008.00731.x","volume":"29","author":"Rosner S.","year":"2008","unstructured":"Rosner S.; Giladi N.; Orr-Urtreger A.; Advances in the genetics of Parkinson\u2019s disease. Acta Pharmacol Sin 2008,29(1),21-34","journal-title":"Acta Pharmacol Sin"},{"key":"ref=10","year":"(Accessed on: 07, July 2019).","unstructured":"Parkinson's disease: Hope through research Available from: (Accessed on: 07, July 2019)."},{"key":"ref=11","doi-asserted-by":"publisher","first-page":"65","DOI":"10.2741\/S415","volume":"6","author":"Beitz J.M.","year":"2014","unstructured":"Beitz J.M.; Parkinson\u2019s disease: A review. Front Biosci (Schol Ed) 2014,6(6),65-74","journal-title":"Front Biosci (Schol Ed)"},{"key":"ref=12","doi-asserted-by":"publisher","first-page":"871","DOI":"10.1136\/jnnp-2015-311890","volume":"87","author":"Noyce A.J.","year":"2016","unstructured":"Noyce A.J.; Lees A.J.; Schrag A.E.; The prediagnostic phase of Parkinson\u2019s disease. J Neurol Neurosurg Psychiatry 2016,87(8),871-878","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"ref=13","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1093\/hmg\/8.1.81","volume":"8","author":"Farrer M.","year":"1999","unstructured":"Farrer M.; Gwinn-Hardy K.; Muenter M.; DeVrieze F.W.; Crook R.; Perez-Tur J.; Lincoln S.; Maraganore D.; Adler C.; Newman S.; MacElwee K.; McCarthy P.; Miller C.; Waters C.; Hardy J.; A chromosome 4p haplotype segregating with Parkinson\u2019s disease and postural tremor. Hum Mol Genet 1999,8(1),81-85","journal-title":"Hum Mol Genet"},{"key":"ref=14","doi-asserted-by":"publisher","first-page":"841","DOI":"10.1126\/science.1090278","volume":"302","author":"Singleton A.B.","year":"2003","unstructured":"Singleton A.B.; Farrer M.; Johnson J.; Singleton A.; Hague S.; Kachergus J.; Hulihan M.; Peuralinna T.; Dutra A.; Nussbaum R.; Lincoln S.; Crawley A.; Hanson M.; Maraganore D.; Adler C.; Cookson M.R.; Muenter M.; Baptista M.; Miller M.; Blancato J.; Hardy J.; Gwinn-Hardy K.; \u03b1-Synuclein locus triplication causes Parkinson\u2019s disease. Science 2003,302(5646),841","journal-title":"Science"},{"key":"ref=15","doi-asserted-by":"publisher","first-page":"408","DOI":"10.1111\/j.1365-2648.2010.05459.x","volume":"67","author":"Haahr A.","year":"2011","unstructured":"Haahr A.; Kirkevold M.; Hall E.O.; Ostergaard K.; Living with advanced Parkinson\u2019s disease: A constant struggle with unpredictability. J Adv Nurs 2011,67(2),408-417","journal-title":"J Adv Nurs"},{"key":"ref=16","doi-asserted-by":"publisher","DOI":"10.1038\/cddis.2012.94","volume":"2012","author":"Marques O.","year":"2012","unstructured":"Marques O.; Outeiro T.F.; Alpha-synuclein: From secretion to dysfunction and death. Cell Death Dis 2012,2012","journal-title":"Cell Death Dis"},{"key":"ref=17","doi-asserted-by":"publisher","DOI":"10.1155\/2016\/1720621","volume":"2016","author":"Xu L.","year":"2016","unstructured":"Xu L.; Pu J.; Alpha-synuclein in parkinson\u2019s disease: From pathogenetic dysfunction to potential clinical application. Parkinsons Dis 2016,2016","journal-title":"Parkinsons Dis"},{"key":"ref=18","doi-asserted-by":"publisher","first-page":"1197","DOI":"10.1126\/science.274.5290.1197","volume":"274","author":"Polymeropoulos M.H.","year":"1996","unstructured":"Polymeropoulos M.H.; Higgins J.J.; Golbe L.I.; Johnson W.G.; Ide S.E.; Di Iorio G.; Sanges G.; Stenroos E.S.; Pho L.T.; Schaffer A.A.; Lazzarini A.M.; Nussbaum R.L.; Duvoisin R.C.; Mapping of a gene for Parkinson\u2019s disease to chromosome 4q21-q23. Science 1996,274(5290),1197-1199","journal-title":"Science"},{"key":"ref=19","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1136\/jnnp.52.Suppl.13","volume":"52","author":"Langston J.W.","year":"1989","unstructured":"Langston J.W.; Current theories on the cause of Parkinson\u2019s disease. J Neurol Neurosurg Psychiatry 1989,52,13-17","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"ref=20","doi-asserted-by":"publisher","first-page":"136","DOI":"10.1038\/ncpneuro0126","volume":"2","author":"Klein C.","year":"2006","unstructured":"Klein C.; Schlossmacher M.G.; The genetics of Parkinson disease: Implications for neurological care. Nat Clin Pract Neurol 2006,2(3),136-146","journal-title":"Nat Clin Pract Neurol"},{"key":"ref=21","doi-asserted-by":"publisher","first-page":"2760","DOI":"10.1093\/brain\/awh676","volume":"128","author":"Brice A.","year":"2005","unstructured":"Brice A.; Genetics of Parkinson\u2019s disease: LRRK2 on the rise. Brain 2005,128(Pt 12),2760-2762","journal-title":"Brain"},{"key":"ref=22","doi-asserted-by":"publisher","first-page":"422","DOI":"10.1056\/NEJMc055540","volume":"354","author":"Lesage S.","year":"2006","unstructured":"Lesage S.; D\u00fcrr A.; Tazir M.; Lohmann E.; Leutenegger A-L.; Janin S.; Pollak P.; Brice A.; LRRK2 G2019S as a cause of Parkinson\u2019s disease in North African Arabs. N Engl J Med French Parkinson\u2019s Disease Genetics Study Group2006,354(4),422-423","journal-title":"N Engl J Med"},{"key":"ref=23","doi-asserted-by":"publisher","first-page":"424","DOI":"10.1056\/NEJMc055509","volume":"354","author":"Ozelius L.J.","year":"2006","unstructured":"Ozelius L.J.; Senthil G.; Saunders-Pullman R.; Ohmann E.; Deligtisch A.; Tagliati M.; Hunt A.L.; Klein C.; Henick B.; Hailpern S.M.; Lipton R.B.; Soto-Valencia J.; Risch N.; Bressman S.B.; LRRK2 G2019S as a cause of Parkinson\u2019s disease in Ashkenazi Jews. N Engl J Med 2006,354(4),424-425","journal-title":"N Engl J Med"},{"key":"ref=24","doi-asserted-by":"publisher","first-page":"9879","DOI":"10.1073\/pnas.1004676107","volume":"107","author":"Tong Y.","year":"2010","unstructured":"Tong Y.; Yamaguchi H.; Giaime E.; Boyle S.; Kopan R.; Kelleher R.J.; Shena J.; Loss of leucine-rich repeat kinase 2 causes impairment of protein degradation pathways, accumulation of alpha-synuclein, and apoptotic cell death in aged mice. Proc Natl Acad Sci USA 2010,107(21),9879-84","journal-title":"Proc Natl Acad Sci USA"},{"key":"ref=25","doi-asserted-by":"publisher","first-page":"595","DOI":"10.1016\/j.neuron.2004.10.023","volume":"44","author":"Pais\u00e1n-Ru\u00edz C.","year":"2004","unstructured":"Pais\u00e1n-Ru\u00edz C.; Jain S.; Evans E.W.; Gilks W.P.; Sim\u00f3n J.; van der Brug M.; de Munain A.L.; Aparicio S.; Gil A.M.; Khan N.; Johnson J.; Martinez J.R.; Nicholl D.; Carrera I.M.; Pena A.S.; de Silva R.; Lees A.; Mart\u00ed-Mass\u00f3 J.F.; P\u00e9rez-Tur J.; Wood N.W.; Singleton A.B.; Cloning of the gene containing mutations that cause PARK8-linked Parkinson\u2019s disease. Neuron 2004,44(4),595-600","journal-title":"Neuron"},{"key":"ref=26","doi-asserted-by":"publisher","first-page":"601","DOI":"10.1016\/j.neuron.2004.11.005","volume":"44","author":"Zimprich A.","year":"2004","unstructured":"Zimprich A.; Biskup S.; Leitner P.; Farrer M.; Lincoln S.; Kachergus J.; Hulihan M.; Uitti R.J.; Calne D.B.; Stoessl A.J.; Pfeiffer R.F.; Patenge N.; Carbajal I.C.; Vieregge P.; Asmus F.; M\u00fcller-Myhsok B.; Dickson D.W.; Meitinger T.; Strom T.M.; Wszolek Z.K.; Gasser T.; Mutations in LRRK2 cause autosomal-dominant parkinsonism with pleomorphic pathology. Neuron 2004,44(4),601-607","journal-title":"Neuron"},{"key":"ref=27","doi-asserted-by":"publisher","first-page":"17510","DOI":"10.1073\/pnas.0405313101","volume":"101","author":"Lo Bianco C.","year":"2004","unstructured":"Lo Bianco C.; Schneider B.L.; Bauer M.; Sajadi A.; Brice A.; Iwatsubo T.; Aebischer P.; Lentiviral vector delivery of parkin prevents dopaminergic degeneration in an alpha-synuclein rat model of Parkinson\u2019s disease. Proc Natl Acad Sci USA 2004,101(50),17510-17515","journal-title":"Proc Natl Acad Sci USA"},{"key":"ref=28","first-page":"67","volume":"16","author":"Miklya I.","year":"2014","unstructured":"Miklya I.; G\u00f6ltl P.; Hafenscher F.; Pencz N.; The role of parkin in Parkinson\u2019s disease. Neuropsychopharmacol Hung 2014,16(2),67-76","journal-title":"Neuropsychopharmacol Hung"},{"key":"ref=29","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pbio.1000298","volume":"8","author":"Narendra D.P.","year":"2010","unstructured":"Narendra D.P.; Jin S.M.; Tanaka A.; Suen D-F.; Gautier C.A.; Shen J.; Cookson M.R.; Youle R.J.; PINK1 is selectively stabilized on impaired mitochondria to activate Parkin. PLoS Biol 2010,8(1)","journal-title":"PLoS Biol"},{"key":"ref=30","doi-asserted-by":"publisher","first-page":"795","DOI":"10.1083\/jcb.200809125","volume":"183","author":"Narendra D.","year":"2008","unstructured":"Narendra D.; Tanaka A.; Suen D.F.; Youle R.J.; Parkin is recruited selectively to impaired mitochondria and promotes their autophagy. J Cell Biol 2008,183(5),795-803","journal-title":"J Cell Biol"},{"key":"ref=31","doi-asserted-by":"publisher","first-page":"706","DOI":"10.1016\/j.ceb.2003.10.015","volume":"15","author":"Bossy-Wetzel E.","year":"2003","unstructured":"Bossy-Wetzel E.; Barsoum M.J.; Godzik A.; Schwarzenbacher R.; Lipton S.A.; Mitochondrial fission in apoptosis, neurodegeneration and aging. Curr Opin Cell Biol 2003,15(6),706-16","journal-title":"Curr Opin Cell Biol"},{"key":"ref=32","doi-asserted-by":"publisher","first-page":"11805","DOI":"10.1523\/JNEUROSCI.2862-09.2010","volume":"30","author":"Um J.W.","year":"2010","unstructured":"Um J.W.; Im, E.; Lee, H.J.; Min, B.; Yoo, L.; Yoo, J.; L\u00fcbbert, H.; Stichel-Gunkel, C.; Cho, H.S.; Yoon, J.B.; Chung, K.C. Parkin directly modulates 26S proteasome activity. J Neurosci 2010,30(35),11805-11814","journal-title":"J Neurosci"},{"key":"ref=33","doi-asserted-by":"publisher","first-page":"560","DOI":"10.1056\/NEJM200005253422103","volume":"342","author":"Lucking C.B.","year":"2000","unstructured":"Lucking C.B.; Durr A.; Bonifati V.; Vaughan J.; De Michele G.; Gasser T.; Harhangi B.S.; Meco G.; Den\u00e8fle P.; Wood N.W.; Agid Y.; Brice A.; European Consortium on Genetic Susceptibility in Parkinson\u2019s Disease. Association between early-onset parkinson\u2019s disease and mutations in the parkin gene- French Parkinson\u2019s Disease Genetics Study Group. N Engl J Med French Parkinson\u2019s Disease Genetics Study Group2000,342,560-1567","journal-title":"N Engl J Med"},{"key":"ref=34","doi-asserted-by":"crossref","first-page":"1158","DOI":"10.1126\/science.1096284","volume":"304","author":"Valente E.M.","year":"2004","unstructured":"Valente E.M.; Abou Sleiman P.M.; Caputo V.; Muqit M.M.K.; Harvey K.; Gispert S.; Ali Z.; Turco D.D.; Bentivoglio A.R.; Healy D.G.; Albanese A.; Nussbaum R.; Gonz\u00e1lez-Maldonado R.; Deller T.; Salvi S.; Cortelli P.; Gilks W.P.; Latchman D.S.; Harvey R.J.; Dallapiccola B.; Auburger G.; Wood N.W.; Hereditary early onset parkinson\u2019s disease caused by mutations in PINK-1. Science 2004,304,1158-1160","journal-title":"Science"},{"key":"ref=35","doi-asserted-by":"crossref","first-page":"11041","DOI":"10.1073\/pnas.0805908105","volume":"105","author":"Favreau P.H.","year":"2008","unstructured":"Favreau P.H.; Hardy J.; PINK-1 in mitochondrial function. Proc Natl Acad Sci USA 2008,105,11041-11042","journal-title":"Proc Natl Acad Sci USA"},{"key":"ref=36","doi-asserted-by":"publisher","first-page":"895","DOI":"10.1086\/319522","volume":"68","author":"Valente E.M.","year":"2001","unstructured":"Valente E.M.; Bentivoglio A.R.; Dixon P.H.; Ferraris A.; Ialongo T.; Frontali M.; Albanese A.; Wood N.W.; Localization of a novel locus for autosomal recessive early-onset parkinsonism, PARK6, on human chromosome 1p35-p36. Am J Hum Genet 2001,68(4),895-900","journal-title":"Am J Hum Genet"},{"key":"ref=37","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1212\/01.wnl.0000167546.39375.82","volume":"65","author":"Bonifati V.","year":"2005","unstructured":"Bonifati V.; Roh\u00e9 C.F.; Breedveld G.J.; Fabrizio E.; De Mari M.; Tassorelli C.; Tavella A.; Marconi R.; Nicholl D.J.; Chien H.F.; Fincati E.; Abbruzzese G.; Marini P.; De Gaetano A.; Horstink M.W.; Maat-Kievit J.A.; Sampaio C.; Antonini A.; Stocchi F.; Montagna P.; Toni V.; Guidi M.; Libera A.D.; Tinazzi M.; De Pandis F.; Fabbrini G.; Goldwurm S.; de Klein A.; Barbosa E.; Lopiano L.; Martignoni E.; Lamberti P.; Vanacore N.; Meco G.; Oostra B.A.; Italian Parkinson Genetics Network. Early-onset parkinsonism associated with PINK1 mutations: Frequency, genotypes, and phenotypes. Neurology 2005,65(1),87-95","journal-title":"Neurology"},{"key":"ref=38","doi-asserted-by":"crossref","first-page":"686","DOI":"10.1093\/brain\/awl005","volume":"129","author":"Ib\u00e1\u00f1ez P.","year":"2006","unstructured":"Ib\u00e1\u00f1ez P.; Lesage S.; Lohmann E.; Thobois S.; De Michele G.; Borg M.; Agid Y.; D\u00fcrr A.; French parkinson\u2019s disease genetics study group-mutational analysis of the PINK-1 gene in early onset parkinsonism in Europe and North Africa. Brain 2006,129,686-694","journal-title":"Brain"},{"key":"ref=39","doi-asserted-by":"publisher","first-page":"871","DOI":"10.4161\/auto.6.7.13286","volume":"6","author":"Geisler S.","year":"2010","unstructured":"Geisler S.; Holmstr\u00f6m K.M.; Treis A.; Skujat D.; Weber S.S.; Fiesel F.C.; Kahle P.J.; Springer W.; The PINK1\/Parkin-mediated mitophagy is compromised by PD-associated mutations. Autophagy 2010,6(7),871-878","journal-title":"Autophagy"},{"key":"ref=40","doi-asserted-by":"publisher","first-page":"1162","DOI":"10.1038\/nature04779","volume":"441","author":"Clark I.E.","year":"2006","unstructured":"Clark I.E.; Dodson M.W.; Jiang C.; Cao J.H.; Huh J.R.; Seol J.H.; Yoo S.J.; Hay B.A.; Guo M.; Drosophila pink1 is required for mitochondrial function and interacts genetically with parkin. Nature 2006,441(7097),1162-1166","journal-title":"Nature"},{"key":"ref=41","doi-asserted-by":"publisher","first-page":"12413","DOI":"10.1523\/JNEUROSCI.0719-07.2007","volume":"27","author":"Exner N.","year":"2007","unstructured":"Exner N.; Treske B.; Paquet D.; Holmstr\u00f6m K.; Schiesling C.; Gispert S.; Carballo-Carbajal I.; Berg D.; Hoepken H-H.; Gasser T.; Kr\u00fcger R.; Winklhofer K.F.; Vogel F.; Reichert A.S.; Auburger G.; Kahle P.J.; Schmid B.; Haass C.; Loss-of-function of human PINK1 results in mitochondrial pathology and can be rescued by parkin. J Neurosci 2007,27(45),12413-12418","journal-title":"J Neurosci"},{"key":"ref=42","doi-asserted-by":"publisher","first-page":"216","DOI":"10.1016\/j.nbd.2007.07.010","volume":"28","author":"Wang H.L.","year":"2007","unstructured":"Wang H.L.; Chou A.H.; Yeh T.H.; Li A.H.; Chen Y-L.; Kuo Y-L.; Tsai S-R.; Yu S-T.; PINK1 mutants associated with recessive Parkinson\u2019s disease are defective in inhibiting mitochondrial release of cytochrome c. Neurobiol Dis 2007,28(2),216-226","journal-title":"Neurobiol Dis"},{"key":"ref=43","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1038\/nrm3028","volume":"12","author":"Youle R.J.","year":"2011","unstructured":"Youle R.J.; Narendra D.P.; Mechanisms of mitophagy. Nat Rev Mol Cell Biol 2011,12(1),9-14","journal-title":"Nat Rev Mol Cell Biol"},{"key":"ref=44","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1016\/S0092-8674(02)01012-7","volume":"111","author":"Liu Y.","year":"2002","unstructured":"Liu Y.; Fallon L.; Lashuel H.A.; Liu Z.; Lansbury P.T.; The UCH-L1 gene encodes two opposing enzymatic activities that affect alpha-synuclein degradation and Parkinson\u2019s disease susceptibility. Cell 2002,111(2),209-218","journal-title":"Cell"},{"key":"ref=45","doi-asserted-by":"publisher","first-page":"451","DOI":"10.1038\/26652","volume":"395","author":"Leroy E.","year":"1998","unstructured":"Leroy E.; Boyer R.; Auburger G.; Leube B.; Ulm G.; Mezey E.; Harta G.; Brownstein M.J.; Jonnalagada S.; Chernova T.; Dehejia A.; Lavedan C.; Gasser T.; Steinbach P.J.; Wilkinson K.D.; Polymeropoulos M.H.; The ubiquitin pathway in Parkinson\u2019s disease. Nature 1998,395(6701),451-452","journal-title":"Nature"},{"key":"ref=46","doi-asserted-by":"publisher","first-page":"839","DOI":"10.1038\/42166","volume":"388","author":"Spillantini M.G.","year":"1997","unstructured":"Spillantini M.G.; Schmidt M.L.; Lee V.M.; Trojanowski J.Q.; Jakes R.; Goedert M.; Alpha-synuclein in Lewy bodies. Nature 1997,388(6645),839-840","journal-title":"Nature"},{"key":"ref=47","first-page":"1","volume":"123706","author":"Jennifer H.K.","year":"2012","unstructured":"Jennifer H.K.; Chin L-S.; Li L.; Ubiquitin C-terminal hydrolase L1 in tumorigenesis. Biochem Res Int 2012,123706,1-10","journal-title":"Biochem Res Int"},{"key":"ref=48","doi-asserted-by":"publisher","first-page":"6365","DOI":"10.1523\/JNEUROSCI.20-17-06365.2000","volume":"20","author":"Kahle P.J.","year":"2000","unstructured":"Kahle P.J.; Neumann M.; Ozmen L.; M\u00fcller V.; Jacobsen H.; Schindzielorz A.; Okochi M.; Leimer U.; van der Putten H.; Probst A.; Kremmer E.; Kretzschmar H.A.; Haass C.; Subcellular localization of wild-type and Parkinson\u2019s disease-associated mutant alpha -synuclein in human and transgenic mouse brain. J Neurosci 2000,20(17),6365-6373","journal-title":"J Neurosci"},{"key":"ref=49","doi-asserted-by":"publisher","first-page":"1200","DOI":"10.1093\/aje\/kwr451","volume":"175","author":"Liu R.","year":"2012","unstructured":"Liu R.; Guo X.; Park Y.; Huang X.; Sinha R.; Freedman N.D.; Hollenbeck A.R.; Blair A.; Chen H.; Caffeine intake, smoking, and risk of Parkinson disease in men and women. Am J Epidemiol 2012,175(11),1200-1207","journal-title":"Am J Epidemiol"},{"key":"ref=50","doi-asserted-by":"publisher","first-page":"256","DOI":"10.1126\/science.1077209","volume":"299","author":"Bonifati V.","year":"2003","unstructured":"Bonifati V.; Rizzu P.; van Baren M.J.; Schaap O.; Breedveld G.J.; Krieger E.; Dekker M.C.J.; Squitieri F.; Ibanez P.; Joosse M.; van Dongen J.W.; Vanacore N.; van Swieten J.C.; Brice A.; Meco G.; van Duijn C.M.; Oostra B.A.; Heutink P.; Mutations in the DJ-1 gene associated with autosomal recessive early-onset parkinsonism. Science 2003,299(5604),256-259","journal-title":"Science"},{"key":"ref=51","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1007\/s00441-004-0922-6","volume":"318","author":"Abou Sleiman P.M.","year":"2004","unstructured":"Abou Sleiman P.M.; Healy D.G.; Wood N.W.; Causes of parkinson\u2019s disease: genetics of DJ 1. Cell Tissue Res 2004,318,185-188","journal-title":"Cell Tissue Res"},{"key":"ref=52","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1016\/j.neuro.2008.01.007","volume":"29","author":"Lev N.","year":"2008","unstructured":"Lev N.; Ickowicz D.; Melamed E.; Offen D.; Oxidative insults induce DJ-1 upregulation and redistribution: implications for neuroprotection. Neurotoxicology 2008,29(3),397-405","journal-title":"Neurotoxicology"},{"key":"ref=53","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1038\/sj.embor.7400074","volume":"5","author":"Taira T.","year":"2004","unstructured":"Taira T.; Saito Y.; Niki T.; Iguchi-Ariga S.M.M.; Takahashi K.; Ariga H.; DJ-1 has a role in antioxidative stress to prevent cell death. EMBO Rep 2004,5(2),213-218","journal-title":"EMBO Rep"},{"key":"ref=54","doi-asserted-by":"publisher","first-page":"9103","DOI":"10.1073\/pnas.0402959101","volume":"101","author":"Canet-Avil\u00e9s R.M.","year":"2004","unstructured":"Canet-Avil\u00e9s R.M.; Wilson M.A.; Miller D.W.; Ahmad R.; McLendon C.; Bandyopadhyay S.; Baptista M.J.; Ringe D.; Petsko G.A.; Cookson M.R.; The Parkinson\u2019s disease protein DJ-1 is neuroprotective due to cysteine-sulfinic acid-driven mitochondrial localization. Proc Natl Acad Sci USA 2004,101(24),9103-9108","journal-title":"Proc Natl Acad Sci USA"},{"key":"ref=55","doi-asserted-by":"publisher","first-page":"722","DOI":"10.1016\/j.bbrc.2004.03.110","volume":"317","author":"Kinumi T.","year":"2004","unstructured":"Kinumi T.; Kimata J.; Taira T.; Ariga H.; Niki E.; Cysteine-106 of DJ-1 is the most sensitive cysteine residue to hydrogen peroxide-mediated oxidation in vivo in human umbilical vein endothelial cells. Biochem Biophys Res Commun 2004,317(3),722-728","journal-title":"Biochem Biophys Res Commun"},{"key":"ref=56","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pbio.0020327","volume":"2","author":"Martinat C.","year":"2004","unstructured":"Martinat C.; Shendelman S.; Jonason A.; Leete T.; Beal T.F.; Yang L.; Floss T.; Abeliovich A.; Sensitivity to oxidative stress in DJ-1-deficient dopamine neurons: An ES- derived cell model of primary Parkinsonism. PLoS Biol 2004,2(11)","journal-title":"PLoS Biol"},{"key":"ref=57","doi-asserted-by":"publisher","first-page":"8506","DOI":"10.1074\/jbc.M311017200","volume":"279","author":"Olzmann J.A.","year":"2004","unstructured":"Olzmann J.A.; Brown K.; Wilkinson K.D.; Rees H.D.; Huai Q.; Ke H.; Levey A.I.; Li L.; Chin L-S.; Familial Parkinson\u2019s disease-associated L166P mutation disrupts DJ-1 protein folding and function. J Biol Chem 2004,279(9),8506-8515","journal-title":"J Biol Chem"},{"key":"ref=58","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1093\/toxsci\/kfi278","volume":"88","author":"Ooe H.","year":"2005","unstructured":"Ooe H.; Taira T.; Iguchi-Ariga S.M.M.; Ariga H.; Induction of reactive oxygen species by bisphenol A and abrogation of bisphenol A-induced cell injury by DJ-1. Toxicol Sci 2005,88(1),114-1126","journal-title":"Toxicol Sci"},{"key":"ref=59","doi-asserted-by":"publisher","first-page":"885","DOI":"10.3892\/ijmm.19.6.885","volume":"19","author":"Koide-Yoshida S.","year":"2007","unstructured":"Koide-Yoshida S.; Niki T.; Ueda M.; Himeno S.; Taira T.; Iguchi-Ariga S.M.M.; Ando Y.; Ariga H.; DJ-1 degrades transthyretin and an inactive form of DJ-1 is secreted in familial amyloidotic polyneuropathy. Int J Mol Med 2007,19(6),885-893","journal-title":"Int J Mol Med"},{"key":"ref=60","doi-asserted-by":"publisher","first-page":"878","DOI":"10.1212\/WNL.0b013e3181d55f38","volume":"74","author":"Chen H.","year":"2010","unstructured":"Chen H.; Huang X.; Guo X.; Mailman R.B.; Park Y.; Kamel F.; Umbach D.M.; Xu Q.; Hollenbeck A.; Schatzkin A.; Blair A.; Smoking duration, intensity, and risk of Parkinson disease. Neurology 2010,74(11),878-884","journal-title":"Neurology"},{"key":"ref=61","doi-asserted-by":"publisher","first-page":"548","DOI":"10.1248\/bpb.b16-01006","volume":"40","author":"Hijioka M.","year":"2017","unstructured":"Hijioka M.; Inden M.; Yanagisawa D.; Kitamura Y.; DJ-1\/PARK7: A new therapeutic target for neurodegenerative disorders. Biol Pharm Bull 2017,40(5),548-552","journal-title":"Biol Pharm Bull"},{"key":"ref=62","doi-asserted-by":"publisher","first-page":"31380","DOI":"10.1074\/jbc.M305878200","volume":"278","author":"Honbou K.","year":"2003","unstructured":"Honbou K.; Suzuki N.N.; Horiuchi M.; Niki T.; Taira T.; Ariga H.; Inagaki F.; The crystal structure of DJ-1, a protein related to male fertility and Parkinson\u2019s disease. J Biol Chem 2003,278(33),31380-31384","journal-title":"J Biol Chem"},{"key":"ref=63","doi-asserted-by":"publisher","first-page":"31372","DOI":"10.1074\/jbc.M304221200","volume":"278","author":"Tao X.","year":"2003","unstructured":"Tao X.; Tong L.; Crystal structure of human DJ-1, a protein associated with early onset Parkinson\u2019s disease. J Biol Chem 2003,278(33),31372-31379","journal-title":"J Biol Chem"},{"key":"ref=64","doi-asserted-by":"publisher","first-page":"9256","DOI":"10.1073\/pnas.1133288100","volume":"100","author":"Wilson M.A.","year":"2003","unstructured":"Wilson M.A.; Collins J.L.; Hod Y.; Ringe D.; Petsko G.A.; The 1.1-A resolution crystal structure of DJ-1, the protein mutated in autosomal recessive early onset Parkinson\u2019s disease. Proc Natl Acad Sci USA 2003,100(16),9256-92561","journal-title":"Proc Natl Acad Sci USA"},{"key":"ref=65","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1016\/S0014-5793(03)00764-6","volume":"549","author":"Huai Q.","year":"2003","unstructured":"Huai Q.; Sun Y.; Wang H.; Chin L.S.; Li L.; Robinson H.; Ke H.; Crystal structure of DJ-1\/RS and implication on familial Parkinson\u2019s disease. FEBS Lett 2003,549(1-3),171-175","journal-title":"FEBS Lett"},{"key":"ref=66","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1186\/1471-2148-4-6","volume":"4","author":"Bandyopadhyay S.","year":"2004","unstructured":"Bandyopadhyay S.; Cookson M.R.; Evolutionary and functional relationships within the DJ1 superfamily. BMC Evol Biol 2004,4,6","journal-title":"BMC Evol Biol"},{"key":"ref=67","doi-asserted-by":"publisher","first-page":"37556","DOI":"10.1074\/jbc.M101730200","volume":"276","author":"Takahashi K.","year":"2001","unstructured":"Takahashi K.; Taira T.; Niki T.; Seino C.; Iguchi-Ariga S.M.M.; Ariga H.; DJ-1 positively regulates the androgen receptor by impairing the binding of PIASx alpha to the receptor. J Biol Chem 2001,276(40),37556-37563","journal-title":"J Biol Chem"},{"key":"ref=68","first-page":"247","volume":"1","author":"Niki T.","year":"2003","unstructured":"Niki T.; Takahashi-Niki K.; Taira T.; Iguchi-Ariga S.M.M.; Ariga H.; DJBP: A novel DJ-1-binding protein, negatively regulates the androgen receptor by recruiting histone deacetylase complex, and DJ-1 antagonizes this inhibition by abrogation of this complex. Mol Cancer Res 2003,1(4),247-261","journal-title":"Mol Cancer Res"},{"key":"ref=69","doi-asserted-by":"publisher","first-page":"144","DOI":"10.1016\/j.nbd.2006.06.004","volume":"24","author":"Inden M.","year":"2006","unstructured":"Inden M.; Taira T.; Kitamura Y.; Yanagida T.; Tsuchiya D.; Takata K.; Yanagisawa D.; Nishimura K.; Taniguchi T.; Kiso, Yoshimoto, Y.K.; Agatsuma, Y.; Koide-Yoshida, S.; Iguchi-Ariga, S.M.M.; Shimohama, S.; Ariga, H. PARK7 DJ-1 protects against degeneration of nigral dopaminergic neurons in Parkinson\u2019s disease rat model. Neurobiol Dis 2006,24(1),144-158","journal-title":"Neurobiol Dis"},{"key":"ref=70","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1080\/10715760100300831","volume":"35","author":"Mitsumoto A.","year":"2001","unstructured":"Mitsumoto A.; Nakagawa Y.; Takeuchi A.; Okawa K.; Iwamatsu A.; Takanezawa Y.; Oxidized forms of peroxiredoxins and DJ-1 on two-dimensional gels increased in response to sublethal levels of paraquat. Free Radic Res 2001,35(3),301-310","journal-title":"Free Radic Res"},{"key":"ref=71","doi-asserted-by":"publisher","first-page":"420","DOI":"10.1093\/brain\/awh054","volume":"127","author":"Bandopadhyay R.","year":"2004","unstructured":"Bandopadhyay R.; Kingsbury A.E.; Cookson M.R.; Reid A.R.; Evans I.M.; Hope A.D.; Pittman A.M.; Lashley T.; Canet-Aviles R.; Miller D.W.; McLendon C.; Strand C.; Leonard A.J.; Abou-Sleiman P.M.; Healy D.G.; Ariga, H.; Wood, N.W.; de Silva, R.; Revesz, T.; Hardy, J.A.; Lees, A.J. The expression of DJ-1 (PARK7) in normal human CNS and idiopathic Parkinson\u2019s disease. Brain 2004,127(Pt 2),420-430","journal-title":"Brain"},{"key":"ref=72","doi-asserted-by":"publisher","first-page":"10816","DOI":"10.1074\/jbc.M509079200","volume":"281","author":"Choi J.","year":"2006","unstructured":"Choi J.; Sullards M.C.; Olzmann J.A.; Rees H.D.; Weintraub S.T.; Bostwick D.E.; Gearing M.; Levey A.I.; Chin L.S.; Li L.; Oxidative damage of DJ-1 is linked to sporadic Parkinson and Alzheimer diseases. J Biol Chem 2006,281(16),10816-10824","journal-title":"J Biol Chem"},{"key":"ref=73","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1038\/sj.cdd.4401704","volume":"13","author":"Shinbo Y.","year":"2006","unstructured":"Shinbo Y.; Niki T.; Taira T.; Ooe H.; Takahashi-Niki K.; Maita C.; Seino C.; Iguchi-Ariga S.M.M.; Ariga H.; Proper SUMO-1 conjugation is essential to DJ-1 to exert its full activities. Cell Death Differ 2006,13(1),96-108","journal-title":"Cell Death Differ"},{"key":"ref=74","doi-asserted-by":"publisher","first-page":"667","DOI":"10.1016\/j.bbrc.2005.11.058","volume":"339","author":"Ito G.","year":"2006","unstructured":"Ito G.; Ariga H.; Nakagawa Y.; Iwatsubo T.; Roles of distinct cysteine residues in S-nitrosylation and dimerization of DJ-1. Biochem Biophys Res Commun 2006,339(2),667-672","journal-title":"Biochem Biophys Res Commun"},{"key":"ref=75","doi-asserted-by":"publisher","first-page":"4854","DOI":"10.1038\/onc.2008.124","volume":"27","author":"Rahman-Roblick R.","year":"2008","unstructured":"Rahman-Roblick R.; Hellman U.; Becker S.; Bader F.G.; Auer G.; Wiman K.G.; Roblick U.J.; Proteomic identification of p53-dependent protein phosphorylation. Oncogene 2008,27(35),4854-4859","journal-title":"Oncogene"},{"key":"ref=76","doi-asserted-by":"publisher","DOI":"10.1155\/2013\/683920","volume":"2013","author":"Ariga H.","year":"2013","unstructured":"Ariga H.; Takahashi-Niki K.; Kato I.; Maita H.; Niki T.; Iguchi-Ariga S.M.; Neuroprotective function of DJ-1 in Parkinson\u2019s disease. Oxid Med Cell Longev 2013,2013","journal-title":"Oxid Med Cell Longev"},{"key":"ref=77","doi-asserted-by":"publisher","first-page":"770","DOI":"10.1002\/mds.26243","volume":"30","author":"Park J.S.","year":"2015","unstructured":"Park J.S.; Blair N.F.; Sue C.M.; The role of ATP13A2 in Parkinson\u2019s disease: Clinical phenotypes and molecular mechanisms. Mov Disord 2015,30(6),770-779","journal-title":"Mov Disord"},{"key":"ref=78","doi-asserted-by":"publisher","first-page":"11803","DOI":"10.1038\/ncomms11803","volume":"7","author":"Bento C.F.","year":"2016","unstructured":"Bento C.F.; Ashkenazi A.; Jimenez-Sanchez M.; Rubinsztein D.C.; The Parkinson\u2019s disease-associated genes ATP13A2 and SYT11 regulate autophagy via a common pathway. Nat Commun 2016,7,11803","journal-title":"Nat Commun"},{"key":"ref=79","doi-asserted-by":"publisher","first-page":"1184","DOI":"10.1038\/ng1884","volume":"38","author":"Ramirez A.","year":"2006","unstructured":"Ramirez A.; Heimbach A.; Gr\u00fcndemann J.; Stiller B.; Hampshire D.; Cid L.P.; Goebel I.; Mubaidin A.F.; Wriekat A-L.; Roeper J.; Al-Din A.; Hillmer A.M.; Karsak M.; Liss B.; Woods C.G.; Behrens M.I.; Kubisch C.; Hereditary parkinsonism with dementia is caused by mutations in ATP13A2, encoding a lysosomal type 5 P-type ATPase. Nat Genet 2006,38(10),1184-1191","journal-title":"Nat Genet"},{"key":"ref=80","doi-asserted-by":"publisher","first-page":"2646","DOI":"10.1093\/hmg\/dds089","volume":"21","author":"Bras J.","year":"2012","unstructured":"Bras J.; Verloes A.; Schneider S.A.; Mole S.E.; Guerreiro R.J.; Mutation of the parkinsonism gene ATP13A2 causes neuronal ceroid-lipofuscinosis. Hum Mol Genet 2012,21(12),2646-2650","journal-title":"Hum Mol Genet"},{"key":"ref=81","unstructured":"Parkinson\u2019s Disease and Environmental Factors Available from"},{"key":"ref=82","doi-asserted-by":"publisher","first-page":"964","DOI":"10.1289\/ehp.0800277","volume":"117","author":"Ritz B.R.","year":"2009","unstructured":"Ritz B.R.; Manthripragada A.D.; Costello S.; Lincoln S.J.; Farrer M.J.; Cockburn M.; Bronstein J.; Dopamine transporter genetic variants and pesticides in Parkinson\u2019s disease. Environ Health Perspect 2009,117(6),964-969","journal-title":"Environ Health Perspect"},{"key":"ref=83","doi-asserted-by":"publisher","first-page":"314","DOI":"10.1001\/archneurol.2011.30","volume":"68","author":"Evatt M.L.","year":"2011","unstructured":"Evatt M.L.; DeLong M.R.; Kumari M.; Auinger P.; McDermott M.P.; Tangpricha V.; High prevalence of hypovitaminosis D status in patients with early Parkinson disease. Arch Neurol Parkinson Study Group DATATOP Investigators2011,68(3),314-319","journal-title":"Arch Neurol"},{"key":"ref=84","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1136\/oem.2010.057448","volume":"68","author":"Kenborg L.","year":"2011","unstructured":"Kenborg L.; Lassen C.F.; Ritz B.; Schernhammer E.S.; Hansen J.; Gatto N.M.; Olsen J.H.; Outdoor work and risk for Parkinson\u2019s disease: a population-based case-control study. Occup Environ Med 2011,68(4),273-278","journal-title":"Occup Environ Med"},{"key":"ref=85","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pgen.1002237","volume":"7","author":"Hamza T.H.","year":"2011","unstructured":"Hamza T.H.; Chen H.; Hill-Burns E.M.; Rhodes S.H.; Montimurro J.; Kay D.M.; Tenesa A.; Kusel V.I.; Sheehan P.; Eaaswarkhanth M.; Yearout D.; Samii A.; Roberts J.W.; Agarwal P.; Bordelon Y.; Park Y.; Wang L.; Gao J.; Vance J.M.; Kendler K.S.; Bacanu S-A.; Scott W.K.; Ritz B.; Nutt J.; Factor S.A.; Zabetian C.P.; Payami H.; Genome-wide gene-environment study identifies glutamate receptor gene GRIN2A as a Parkinson\u2019s disease modifier gene via interaction with coffee. PLoS Genet 2011,7(8)","journal-title":"PLoS Genet"},{"key":"ref=86","doi-asserted-by":"publisher","first-page":"866","DOI":"10.1289\/ehp.1002839","volume":"119","author":"Tanner C.M.","year":"2011","unstructured":"Tanner C.M.; Kamel F.; Ross G.W.; Hoppin J.A.; Goldman S.M.; Korell M.; Marras C.; Bhudhikanok G.S.; Kasten M.; Chade A.R.; Comyns K.; Richards M.B.; Meng C.; Priestley B.; Fernandez H.H.; Cambi F.; Umbach D.M.; Blair A.; Sandler D.P.; Langston J.W.; Rotenone, paraquat, and Parkinson\u2019s disease. Environ Health Perspect 2011,119(6),866-872","journal-title":"Environ Health Perspect"},{"key":"ref=87","doi-asserted-by":"publisher","first-page":"1652","DOI":"10.1002\/mds.25216","volume":"27","author":"Goldman S.M.","year":"2012","unstructured":"Goldman S.M.; Kamel F.; Ross G.W.; Bhudhikanok G.S.; Hoppin J.A.; Korell M.; Marras C.; Meng C.; Umbach D.M.; Kasten, M.; Chade, A.R.; Comyns, K.; Richards, M.B.; Sandler, D.P.; Blair, A.; Langston, J.W.; Tanner, C.M. Genetic modification of the association of paraquat and Parkinson\u2019s disease. Mov Disord 2012,27(13),1652-1658","journal-title":"Mov Disord"},{"key":"ref=88","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1016\/j.parkreldis.2013.09.023","volume":"20","author":"Kamel F.","year":"2014","unstructured":"Kamel F.; Goldman S.M.; Umbach D.M.; Chen H.; Richardson G.; Barber M.R.; Meng C.; Marras C.; Korell M.; Kasten M.; Hoppin J.A.; Comyns K.; Chade A.; Blair A.; Bhudhikanok G.S.; Ross W.G.; Langston J.W.; Sandler D.P.; Tanner C.M.; Dietary fat intake, pesticide use, and Parkinson\u2019s disease. Parkinsonism Relat Disord 2014,20(1),82-87","journal-title":"Parkinsonism Relat Disord"},{"key":"ref=89","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1146\/annurev-pharmtox-011613-135937","volume":"54","author":"Goldman S.M.","year":"2014","unstructured":"Goldman S.M.; Environmental toxins and Parkinson\u2019s disease. Annu Rev Pharmacol Toxicol 2014,54,141-164","journal-title":"Annu Rev Pharmacol Toxicol"},{"key":"ref=90","unstructured":"NINDS (National Institute of Neorological Disorders and Stroke) Parkinson\u2019s disease: Hope through research. Available from:"},{"key":"ref=91","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1212\/WNL.0b013e3181ea1597","volume":"75","author":"Xu Q.","year":"2010","unstructured":"Xu Q.; Park Y.; Huang X.; Hollenbeck A.; Blair A.; Schatzkin A.; Chen H.; Physical activities and future risk of Parkinson disease. Neurology 2010,75(4),341-348","journal-title":"Neurology"},{"key":"ref=92","doi-asserted-by":"publisher","first-page":"539","DOI":"10.1002\/mds.25787","volume":"29","author":"Li F.","year":"2014","unstructured":"Li F.; Harmer P.; Liu Y.; Eckstrom E.; Fitzgerald K.; Stock R.; Chou L-S.; A randomized controlled trial of patient-reported outcomes with tai chi exercise in Parkinson\u2019s disease. Mov Disord 2014,29(4),539-545","journal-title":"Mov Disord"},{"key":"ref=93","doi-asserted-by":"publisher","first-page":"2395","DOI":"10.1093\/hmg\/ddq113","volume":"19","author":"Chen J.","year":"2010","unstructured":"Chen J.; Li L.; Chin L.S.; Parkinson disease protein DJ-1 converts from a zymogen to a protease by carboxyl-terminal cleavage. Hum Mol Genet 2010,19(12),2395-2408","journal-title":"Hum Mol Genet"},{"key":"ref=94","doi-asserted-by":"publisher","first-page":"15","DOI":"10.3988\/jcn.2012.8.1.15","volume":"8","author":"Shin H.W.","year":"2012","unstructured":"Shin H.W.; Chung S.J.; Drug-induced parkinsonism. J Clin Neurol 2012,8(1),15-21","journal-title":"J Clin Neurol"},{"key":"ref=95","doi-asserted-by":"publisher","first-page":"83","DOI":"10.2147\/JPRLS.S99197","volume":"6","author":"Blanchet P.","year":"2016","unstructured":"Blanchet P.; Kivenko V.; Drug-induced parkinsonism: diagnosis and management. J Parkinson Rest Legs Syndr 2016,6,83-91","journal-title":"J Parkinson Rest Legs Syndr"},{"key":"ref=96","doi-asserted-by":"publisher","first-page":"808","DOI":"10.1016\/j.parkreldis.2014.05.011","volume":"20","author":"Brigo F.","year":"2014","unstructured":"Brigo F.; Erro R.; Marangi A.; Bhatia K.; Tinazzi M.; Differentiating drug-induced parkinsonism from Parkinson\u2019s disease: An update on non-motor symptoms and investigations. Parkinsonism Relat Disord 2014,20(8),808-814","journal-title":"Parkinsonism Relat Disord"},{"key":"ref=97","first-page":"880","volume":"9","author":"Mena M.A.","year":"2009","unstructured":"Mena M.A.; Casarejos M.J.; Solano R.M.; de Y\u00e9benes J.G.; Half a century of L-DOPA. Curr Top Med Chem 2009,9(10),880-893","journal-title":"Curr Top Med Chem"},{"key":"ref=98","doi-asserted-by":"publisher","first-page":"627","DOI":"10.1517\/14656561003598919","volume":"11","author":"Pezzoli G.","year":"2010","unstructured":"Pezzoli G.; Zini M.; Levodopa in Parkinson\u2019s disease: from the past to the future. Expert Opin Pharmacother 2010,11(4),627-635","journal-title":"Expert Opin Pharmacother"},{"key":"ref=99","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0035695","volume":"7","author":"Kim T.H.","year":"2012","unstructured":"Kim T.H.; Cho K.H.; Jung W.S.; Lee M.S.; Herbal medicines for Parkinson\u2019s disease: A systematic review of randomized controlled trials. PLoS One 2012,7(5)","journal-title":"PLoS One"},{"key":"ref=100","doi-asserted-by":"publisher","DOI":"10.1093\/med\/9780199206773.001.0001","author":"Ernst E.","year":"2008","unstructured":"Ernst E.; Pittler M.H.; Wider B.; Boddy K.;  General issues Oxford Handbook of Complementary Medicine 2008","journal-title":"General issues Oxford Handbook of Complementary Medicine"},{"key":"ref=101","first-page":"650","volume":"94","author":"Ernst E.","year":"2001","unstructured":"Ernst E.; Pittler M.H.; Wider B.; Boddy K.; The Desktop guide to complementary and alternative medicine: An evidence-based approach. R. Soc Med 2001,94,650-651","journal-title":"Soc Med"},{"key":"ref=102","doi-asserted-by":"publisher","first-page":"602","DOI":"10.1136\/pmj.76.900.602","volume":"76","author":"M\u00fcnchau A.","year":"2000","unstructured":"M\u00fcnchau A.; Bhatia K.P.; Pharmacological treatment of Parkinson\u2019s disease. Postgrad Med J 2000,76(900),602-610","journal-title":"Postgrad Med J"},{"key":"ref=103","unstructured":"Medications for parkinson\u2019s diseaseAvailable from: Drugs.com","journal-title":"Medications for parkinson\u2019s diseaseAvailable from:"},{"key":"ref=104","unstructured":"Medications for Parkinson\u2019s Available from:, American Parkinson Disease Association","journal-title":"Medications for Parkinson\u2019s Available from:,"},{"key":"ref=105","unstructured":"Medications used to treat Parkinson\u2019sAvailable from:, ParkinsonsDisease.net","journal-title":"Medications used to treat Parkinson\u2019sAvailable from:,"},{"key":"ref=106","doi-asserted-by":"publisher","first-page":"685","DOI":"10.2174\/187152711797247795","volume":"10","author":"Ponce F.A.","year":"2011","unstructured":"Ponce F.A.; Lozano A.M.; The surgical management of Parkinson\u2019s disease. CNS Neurol Disord Drug Targets 2011,10(6),685-692","journal-title":"CNS Neurol Disord Drug Targets"},{"key":"ref=107","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1002\/mds.27228","volume":"33","author":"Lozano C.S.","year":"2018","unstructured":"Lozano C.S.; Tam J.; Lozano A.M.; The changing landscape of surgery for Parkinson\u2019s disease. Mov Disord 2018,33(1),36-47","journal-title":"Mov Disord"},{"key":"ref=108","doi-asserted-by":"publisher","first-page":"134","DOI":"10.2183\/pjab1945.29.134","volume":"29","author":"Narabayashi H.","year":"1953","unstructured":"Narabayashi H.; Okuma T.; Procaine-oil blocking of the globus pallidus for the treatment of rigidity and tremor of parkinsonism. Proc Jpn Acad 1953,29,134-137","journal-title":"Proc Jpn Acad"},{"key":"ref=109","first-page":"441","volume":"25","author":"Hassler R.","year":"1954","unstructured":"Hassler R.; Riechert T.; Indications and localization of stereotactic brain operations. Nervenarzt 1954,25(11),441-447","journal-title":"Nervenarzt"},{"key":"ref=110","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1126\/science.121.3137.217","volume":"121","author":"Cooper I.S.","year":"1955","unstructured":"Cooper I.S.; Chemopallidectomy: An investigative technique in geriatric parkinsonians. Science 1955,121(3137),217-218","journal-title":"Science"},{"key":"ref=111","doi-asserted-by":"publisher","first-page":"1221","DOI":"10.1016\/S0140-6736(80)91680-3","volume":"1","author":"Brice J.","year":"1980","unstructured":"Brice J.; McLellan L.; Suppression of intention tremor by contingent deep-brain stimulation. Lancet 1980,1(8180),1221-1222","journal-title":"Lancet"},{"key":"ref=112","author":"Web M.D.","unstructured":"Web M.D.;  Surgery for Parkinson\u2019s disease Available from:  (Accessed on: July 10, 2019)","journal-title":"Surgery for Parkinson\u2019s disease Available from:"},{"key":"ref=113","unstructured":"What are surgical options to treat Parkinson\u2019s? Available from: ParkinsonsDisease.net","journal-title":"What are surgical options to treat Parkinson\u2019s? Available from:"},{"key":"ref=114","year":"2019","unstructured":"Parkinson\u2019s Foundation. Deep brain stimulation (DBS). Available from:)2019"},{"key":"ref=115","doi-asserted-by":"publisher","first-page":"2077","DOI":"10.1056\/NEJMoa0907083","volume":"362","author":"Follett K.A.","year":"2010","unstructured":"Follett K.A.; Weaver F.M.; Stern M.; Hur K.; Harris C.L.; Luo P.; Marks W.J.; Rothlind J.; Sagher O.; Moy C.; Pahwa R.; Burchiel K.; Hogarth P.; Lai E.C.; Duda J.E.; Holloway K.; Samii A.; Horn S.; Bronstein J.M.; Stoner G.; Starr P.A.; Simpson R.; Baltuch G.; De Salles A.; Huang G.D.; Reda D.J.; CSP 468 Study Group. Pallidal versus subthalamic deep-brain stimulation for Parkinson\u2019s disease. N Engl J Med CSP 468 Study Group2010,362(22),2077-2091","journal-title":"N Engl J Med"},{"key":"ref=116","year":"2019","unstructured":"Surgical treatments. Available from:  (Accessed on: July 10,)2019"},{"key":"ref=117","doi-asserted-by":"publisher","first-page":"1596","DOI":"10.1093\/brain\/awl346","volume":"130","author":"Stefani A.","year":"2007","unstructured":"Stefani A.; Lozano A.M.; Peppe A.; Stanzione P.; Galati S.; Tropepi D.; Pierantozzi M.; Brusa L.; Scarnati E.; Mazzone P.; Bilateral deep brain stimulation of the pedunculopontine and subthalamic nuclei in severe Parkinson\u2019s disease. Brain 2007,130(Pt 6),1596-1607","journal-title":"Brain"},{"key":"ref=118","doi-asserted-by":"publisher","first-page":"1248","DOI":"10.1227\/NEU.0b013e31822b6f71","volume":"69","author":"Thevathasan W.","year":"2011","unstructured":"Thevathasan W.; Coyne T.J.; Hyam J.A.; Kerr G.; Jenkinson N.; Aziz T.Z.; Silburn P.A.; Pedunculopontine nucleus stimulation improves gait freezing in Parkinson disease. Neurosurgery 2011,69(6),1248-1253","journal-title":"Neurosurgery"},{"key":"ref=119","doi-asserted-by":"publisher","first-page":"1412","DOI":"10.1001\/jamaneurol.2017.3098","volume":"74","author":"Bond A.E.","year":"2017","unstructured":"Bond A.E.; Shah B.B.; Huss D.S.; Dallapiazza R.F.; Warren A.; Harrison M.B.; Sperling S.A.; Wang X-Q.; Gwinn R.; Wit J.; Ro S.; Elias W.J.; Safety and efficacy of focused ultrasound thalamotomy for patients with medication-refractory, tremor-dominant parkinson disease: A randomized clinical trial. JAMA Neurol 2017,74(12),1412-1418","journal-title":"JAMA Neurol"},{"key":"ref=120","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1016\/S1474-4422(17)30403-9","volume":"17","author":"Mart\u00ednez-Fern\u00e1ndez R.","year":"2018","unstructured":"Mart\u00ednez-Fern\u00e1ndez R.; Rodr\u00edguez-Rojas R.; Del \u00c1lamo M.; Hern\u00e1ndez-Fern\u00e1ndez F.; Pineda-Pardo J.A.; Dileone M.; Alonso-Frech F.; Foffani G.; Obeso I.; Gasca-Salas C.; de Luis-Pastor E.; Vela L.; Obeso J.A.; Focused ultrasound subthalamotomy in patients with asymmetric Parkinson\u2019s disease: A pilot study. Lancet Neurol 2018,17(1),54-63","journal-title":"Lancet Neurol"},{"key":"ref=121","doi-asserted-by":"publisher","first-page":"487","DOI":"10.1038\/mt.2013.281","volume":"22","author":"Bartus R.T.","year":"2014","unstructured":"Bartus R.T.; Weinberg M.S.; Samulski R.J.; Parkinson\u2019s disease gene therapy: success by design meets failure by efficacy. Mol Ther 2014,22(3),487-497","journal-title":"Mol Ther"},{"key":"ref=122","doi-asserted-by":"publisher","first-page":"413","DOI":"10.3233\/JPD-150630","volume":"5","author":"George S.","year":"2015","unstructured":"George S.; Brundin P.; Immunotherapy in Parkinson\u2019s disease: Micromanaging alpha-synuclein aggregation. J Parkinsons Dis 2015,5(3),413-424","journal-title":"J Parkinsons Dis"},{"key":"ref=123","doi-asserted-by":"publisher","first-page":"1551","DOI":"10.1177\/0963689717735411","volume":"26","author":"Yasuhara T.","year":"2017","unstructured":"Yasuhara T.; Kameda M.; Sasaki T.; Tajiri N.; Date I.; Cell therapy for Parkinson\u2019s disease. Cell Transplant 2017,26(9),1551-1559","journal-title":"Cell Transplant"}],"container-title":["Central Nervous System Agents in Medicinal Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/eurekaselect.com\/article\/download\/183489","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.eurekaselect.com\/183489\/article","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/eurekaselect.com\/article\/download\/183489","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,2,19]],"date-time":"2021-02-19T12:45:22Z","timestamp":1613738722000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.eurekaselect.com\/183489\/article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,9,29]]},"references-count":123,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2020,9,29]]}},"alternative-id":["LiveAll1"],"URL":"https:\/\/doi.org\/10.2174\/1871524920666200705222842","relation":{},"ISSN":["1871-5249"],"issn-type":[{"value":"1871-5249","type":"print"}],"subject":[],"published":{"date-parts":[[2020,9,29]]},"assertion":[{"value":"Peer Reviewed","order":0,"name":"review_status","label":"Review Status","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Single blind","order":1,"name":"review_process","label":"Review Process","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Checked with iThenticate","order":0,"name":"screening_status","label":"Screening Status","group":{"name":"plagiarism_screening","label":"Plagiarism Screening"}},{"value":"2020-03-29","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-06-18","order":1,"name":"revised","label":"Revised","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-06-22","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-09-29","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}